Eli Lilly Balances Alzheimer's Reimbursement Win Against Widening 340B Discount Battle

Eli Lilly's push to broaden patient access to its medicines scored a fresh win north of the border this week, even as a legal fight over its discount-data demands in the U.S. threatens to complicate the commercial runway. Canada's drug agency has recommended reimbursement for Kisunla (donanemab) in eligible adults with early symptomatic Alzheimer's disease, the company said, a decision that centers on coverage rather than any new marketing approval.

The Canadian endorsement landed alongside a burst of clinical and corporate news that has kept Lilly in the headlines. On Oct. 28 the company reported positive topline results from TRANSCEND-T2D-2, a Phase 3 head-to-head study in which retatrutide met its primary and key secondary endpoints in adults with type 2 diabetes compared with Ozempic. After 80 weeks, average A1C reduction reached 2.2% on retatrutide versus 1.8% for the comparator, while mean weight loss came in at 44–47 lb against 21 lb — a reduction Lilly described as more than twice as large.

Cancer Data and a Payout Date

Oncology readouts filled out the pipeline picture. On Oct. 24 Lilly disclosed Phase 1 results for the experimental agent sofetabart mipitecan combined with bevacizumab in patients with platinum-sensitive ovarian cancer, posting a confirmed objective response rate of 79% and a disease control rate of 100% — early-stage data for a treatment still under investigation. A day later came first-line data for experimental olomorasib in non-small cell lung cancer harboring the KRAS-G12C mutation, with initial randomized results from the Phase 3 SUNRAY-01 trial expected in the first half of 2027.

Shareholders also got a distribution date. Lilly's board on Oct. 26 declared a fourth-quarter 2026 dividend of $1.73 per share, payable Dec. 10 to holders of record as of Nov. 13.

The 340B Dispute Takes Center Stage

Offsetting that momentum is a legal challenge that has been building on two fronts. Five Massachusetts hospitals have sued over Lilly's data-reporting requirements under the 340B discount program, according to media reports on Wednesday. The hospitals are seeking to halt the contested rule and restore discounted pricing, while Lilly maintains that the hospitals' refusal to share data reflects concerns about potential misuse of the program. The two sides remain far apart: the clinics are fighting the conditions attached to their discounts, and Lilly is holding firm on its information demands.

Should investors sell immediately? Or is it worth buying Eli Lilly?

The pressure isn't confined to the courtroom. In Missouri, Attorney General Catherine Hanaway issued an order on Oct. 26 directing an end to the required transmission of detailed claims data as a condition for discounted prices, a directive that also covers the use of data already collected. Her office warned of possible enforcement action for noncompliance. For investors, the risk crystallizes if Lilly is forced to alter its requirements or absorb further legal costs — developments that would narrow an otherwise favorable operating picture.

Revenue Guidance Is the Real Scorecard

What ultimately matters for the stock is whether Lilly can deliver on its raised outlook. Roughly a week ago the company lifted its 2026 revenue forecast to $91.0–92.0 billion, a range that now serves as the yardstick for confidence in the current fiscal year. Reuters tied the increase to robust demand for Mounjaro and Zepbound, giving the growth story a solid operating foundation as long as that demand holds. The discount fight gains economic weight only if it hinders execution against those targets.

Third-quarter 2026 revenue came in at $24.4 billion, up 39%, a pace that reinforces expectations of further expansion while raising the bar for coming results: they must show Lilly can sustain the higher revenue base. The central question is durability of growth under tougher legal and commercial conditions.

A New Self-Pay Channel

Supporting the demand side is a fresh access route. Under an agreement announced yesterday with Hims & Hers, eligible patients with a prescription will be able to obtain Foundayo and Zepbound through the platform at self-pay prices, with monthly costs starting at $149 for Foundayo and $299 for Zepbound, according to the company. That channel could bolster the business if patients actually use it and generate incremental demand.

Research offers another potential prop. The Oct. 28 Phase 3 topline results for retatrutide against Ozempic in adults with type 2 diabetes point to further development upside, provided the positive findings hold up in later stages. In the favorable scenario, the existing franchise, broader patient access and pipeline progress reinforce one another.

What to Watch Next

The bullish case rests on sustained demand and additional access to Lilly's medicines; the bear case hinges on whether the 340B conflict reshapes business practices or adds costs. As long as Mounjaro and Zepbound demand carries and the revenue range stays within reach, the operating outlook holds. Should the discount dispute materially burden how Lilly does business, investors would need to reweigh the growth opportunity against those consequences.

A concrete near-term checkpoint comes at the American College of Rheumatology meeting from Nov. 6–11, 2026, where Lilly has slated presentations including Phase 3 results for retatrutide in knee osteoarthritis and obesity, plus one-year data from the Phase 3b study of Taltz plus Zepbound in psoriatic arthritis with obesity. Convincing medical benefit there could strengthen the long-term case. For the shares, two valuation questions now converge: how durable the additional therapeutic potential proves to be, and how well Lilly defends its expanding business against the legal risks.

Ad

Eli Lilly Stock: New Analysis - 8 November

Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Eli Lilly analysis...